Strong CapitalizationA high equity ratio and low debt-to-equity provide durable financial flexibility for a pharma manufacturer. This strength supports sustained investment in regulatory compliance, capacity expansion and R&D without excessive refinancing risk, improving resilience to industry shocks.

Integrated API And FDF ModelOwning capabilities across APIs and finished dosages gives structural advantages: margin capture at multiple stages, diversified revenue streams and cross-selling into domestic and export markets. This reduces single-product concentration and supports steady demand over time.

Healthy Gross And Improved EBIT MarginsA strong gross margin and materially improved EBIT margin indicate effective cost control and operating leverage. Sustainable operational efficiency enhances cash generation potential and provides room to invest in quality, capacity and product development long-term.

Bears Say

Negative Free Cash FlowPersistent negative free cash flow despite positive operating cash flow signals heavy capital spending or working capital strain. Poor conversion from accounting profits to cash can constrain funding for growth, dividends or compliance capex and may require external financing.

Declining Net Margin And ROEFalling net margins and lower ROE point to pressure on the company's ability to convert sales into shareholder returns. If sustained, this reduces internal funding capacity, weakens competitive returns versus peers and may signal pricing, cost or product-mix challenges.

Sharp EPS ContractionA large negative EPS growth rate reflects significant earnings volatility or one-off impacts that erode per-share profitability. Continued EPS deterioration undermines investor confidence, limits retained earnings for reinvestment and raises vulnerability to funding shocks.

Kopran Limited News

Kopran Closes Trading Window Ahead of Q3 Results Under SEBI Norms

Kopran Limited ( ($IN:KOPRAN) ) has provided an update. Kopran Limited has announced that its trading window for...

3M ago

Kopran Limited Announces Board Changes

Kopran Limited ( ($IN:KOPRAN) ) has shared an announcement. Kopran Limited has announced changes in its Board of...

6M ago

KOPRAN FAQ

What was Kopran Limited’s price range in the past 12 months?

Kopran Limited lowest stock price was ₹115.65 and its highest was ₹214.65 in the past 12 months.

What is Kopran Limited’s market cap?

Kopran Limited’s market cap is ₹5.63B.

When is Kopran Limited’s upcoming earnings report date?

Kopran Limited’s upcoming earnings report date is May 21, 2026 which is in 66 days.

How were Kopran Limited’s earnings last quarter?

Kopran Limited released its earnings results on Jan 22, 2026. The company reported ₹1.934 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.934.

Is Kopran Limited overvalued?

According to Wall Street analysts Kopran Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kopran Limited pay dividends?

Kopran Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 1.96%. See more information on Kopran Limited dividends here

What is Kopran Limited’s EPS estimate?

Kopran Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kopran Limited have?

Kopran Limited has 48,285,606 shares outstanding.

What happened to Kopran Limited’s price movement after its last earnings report?

Kopran Limited reported an EPS of ₹1.934 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.111%.

Which hedge fund is a major shareholder of Kopran Limited?

Currently, no hedge funds are holding shares in IN:KOPRAN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kopran Limited

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.